2024
Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies
Issa N, Chovatiya R, Talia J, Torres T, Eyerich K, Calimlim B, Yang Y, Pechonkina A, Moreira A, Grada A, Bunick C. Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies. SKIN The Journal Of Cutaneous Medicine 2024, 8: s449. DOI: 10.25251/skin.8.supp.449.Peer-Reviewed Original ResearchAtopic dermatitisModerate-to-severe atopic dermatitisLong-term disease controlClinically meaningful responseProlonged systemic therapyProportion of patientsUpadacitinib treatmentOptimal treatment targetsSystemic therapyOptimal treatmentMeaningful responseJAK inhibitorsInterim analysisPatientsUpadacitinibLong-term maintenanceTreatment targetItchingOptimal outcomesWeeksDermatitisDisease controlOutcomesSkinPhase 3
2023
42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
Silverberg J, Deleuran M, Gold L, Bunick C, Hijnen D, Calimlim B, Teixeira H, Platt A, Grada A, Hu X, Gooderham M. 42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up). Journal Of The American Academy Of Dermatology 2023, 89: ab90. DOI: 10.1016/j.jaad.2023.07.365.Peer-Reviewed Original ResearchTopical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study
Marathe K, Teng J, Guenthner S, Bunick C, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D. Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study. Dermatology And Therapy 2023, 13: 1255-1264. PMID: 37170057, PMCID: PMC10264299, DOI: 10.1007/s13555-023-00923-1.Peer-Reviewed Original ResearchSignificant laboratory changesLaboratory changesCongenital ichthyosisLaboratory parameter changesRelevant laboratory abnormalitiesPhase 2b studyWeeks of treatmentYears of ageSingle reportCI subtypesIsotretinoin treatmentStudy discontinuationSystemic isotretinoinUrinalysis abnormalitiesLaboratory abnormalitiesOral retinoidsTreatment cohortsVehicle treatmentDrug withdrawalLaboratory valuesLeukocyte esteraseUrea nitrogenControl studyWeeksNeutropenia